RxDoctor Payments Data

Pradeep Agarwal, MD

Interventional Cardiology · Peoria, AZNPI 1780653840

Payments from drug & device makers

$4,404in general payments, 2019–2025

Across 95 payments — averaging $46.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$411
  • Abiomed$375
  • Medtronic$241
  • E.r. Squibb & Sons, L.L.C.$132
  • plus $331 from 11 others

What the payments were for

  • Travel & lodging$1,41832%
  • Food & beverage$2,96867%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,404 in reported general payments places this provider in the 20th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$985,803
Medicare patients
1,584
Services billed
12,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,075$1,284,871
XareltoRivaroxaban130$155,557
Repatha SureclickEvolocumab46$50,541
BrilintaTicagrelor43$34,199
EntrestoSacubitril/Valsartan25$26,890
JardianceEmpagliflozin12$12,928
FarxigaDapagliflozin Propanediol18$12,326
Dabigatran EtexilateDabigatran Etexilate Mesylate29$11,318
Flecainide Acetate221$8,537
Diltiazem 24hr Er (Cd)Diltiazem Hcl304$7,787
Metoprolol Succinate511$7,175
Losartan Potassium466$4,610
Ranolazine ErRanolazine63$4,575
Midodrine Hcl50$4,433
Bumetanide129$3,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$1,284,8711,075 claims
Johnson & JohnsonXarelto$12$155,557130 claims
NovartisEntresto$62$26,89025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →